PETALING JAYA: Eight patients have been enrolled in a new randomised controlled trial looking into the efficacy among high-risk Covid-19 patients of the anti-parasitic drug Ivermectin which was once touted as a wonder drug.
The drug has been claimed to be able to prevent deaths and the worsening of mild Covid-19 symptoms.
Health director-general Dr Noor Hisham Abdullah in a statement said the first patient for the study was admitted on May 31. The study, led by a specialist in Ipoh, is expected to be completed by September.
The study will enrol 500 subjects from high-risk groups, those who are 50 years old and…
